Current treatment of COVID-19 in renal patients: hope or hype?

To date the severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2), known as COVID-19, is for clinicians the most difficult global therapeutic problem. In this landscape, the management of patients with chronic kidney disease, acute kidney injury or patients undergoing immunosuppressant thera...

Full description

Saved in:
Bibliographic Details
Published in:Internal and emergency medicine 2020-11, Vol.15 (8), p.1389-1398
Main Authors: Roberto, Palumbo, Francesco, Londrino, Emanuela, Cordova, Giorgia, Gambardella, Pasquale, Niscola, Sara, Dominijanni
Format: Article
Language:English
Subjects:
Adenosine Monophosphate - analogs & derivatives
Adenosine Monophosphate - therapeutic use
Adrenal Cortex Hormones - therapeutic use
Alanine - analogs & derivatives
Alanine - therapeutic use
Amides - therapeutic use
Antibodies, Monoclonal - therapeutic use
Antiviral drugs
Cobicistat - therapeutic use
Coronavirus Infections - complications
Coronavirus Infections - drug therapy
Coronaviruses
COVID-19
COVID-19 : diagnosis
Darunavir - therapeutic use
Drug Combinations
Humans
Im - Review
Internal Medicine
Kidney - drug effects
Kidney - injuries
Kidney - physiopathology
Kidney diseases
Kidney transplantation
Lopinavir - therapeutic use
management and prognosis
Medicine
Medicine & Public Health
Nephrology
Pandemics
Patients
Pneumonia, Viral - complications
Pneumonia, Viral - drug therapy
Pyrazines - therapeutic use
Renal function
Renal Insufficiency, Chronic - complications
Renal Insufficiency, Chronic - drug therapy
Renal Replacement Therapy - methods
Ritonavir - therapeutic use
Severe acute respiratory syndrome coronavirus 2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To date the severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2), known as COVID-19, is for clinicians the most difficult global therapeutic problem. In this landscape, the management of patients with chronic kidney disease, acute kidney injury or patients undergoing immunosuppressant therapies for kidney transplant or glomerular diseases, represent a clinical challenge for nephrologists, especially in patients with severe acute lung involvement. Therefore in this setting, due to the lack of anti-COVID treatment schedules, tailored management is mandatory to reduce the side effects, as consequence of impaired renal function and drugs interactions. We report the main treatment actually used against SARS-CoV-2, underlining its possible use in the nephropatic patients and the central role of nephrologists to improve the clinical outcome.
ISSN:1828-0447
1970-9366
DOI:10.1007/s11739-020-02510-0